By Herman Sanchez & Andrew Combs
There’s no doubt that partnerships and M&As are key growth drivers in the biopharma industry. But for collaborative relationships to occur, understanding the value of a company’s underlying assets is critical.
Forecast and valuation engagements in the life sciences industry have grown following recent venture investment trends. According to Evaluate, between 2012 and 2017, both total investments and average investments per financing event increased by about 20 percent each year.